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Background:  In spite of its success in reducing restenosis, paclitaxel-eluting stents are known to be less effective than other drug-eluting stents 
(DES). Based on the reduced efficacy of drugs caused by drug-resistance in cancer cells, we tested whether vascular smooth muscle cells (VSMCs) 
have the drug-resistance, and investigated its underlying mechanism.
Methods and Results:  First, we tested the expression level of several drug-resistance genes in VSMCs. Multidrug resistance-1 (MDR-1), one of 
the most important drug-resistance genes in relation to paclitaxel, was not expressed in VSMCs. Interestingly, although initial paclitaxel decreased 
the number of viable cells, the number began to increase again after one or two weeks of culture with paclitaxel. Paclitaxel increased the level 
of MDR-1 in a time-dependent manner, suggesting that paclitaxel itself induces drug-resistance to paclitaxel. In vivo studies demonstrated that 
paclitaxel induced MDR-1-positive area in the neointima. Further experiments showed that paclitaxel at first increases the level of cyclooxygenase-2 
(COX-2), finally leading to the induction of MDR-1, which was also confirmed in vivo. Another study with isotope-tagged paclitaxel proved that the 
paclitaxel-induced MDR-1 is fully functional. The overexpression of MDR-1 reversed the viability of cells reduced by paclitaxel treatment, suggesting 
the important role of MDR-1 in the modulation of VSMC viability. In vivo studies also showed that the overexpression of MDR-1 reversed the effect 
of paclitaxel in reducing neointimal formation, suggesting that paclitaxel-induced MDR-1 could reduce the efficacy of paclitaxel. In addition, the use 
of paclitaxel with COX-2 inhibitor showed additional effect in reducing neointima, suggesting that COX-2 inhibition might be effective in blocking the 
increase of MDR-1 induced by paclitaxel.
Conclusions:  This study demonstrated that paclitaxel induces drug-resistance by the induction of COX-2 and MDR-1, finally decreasing the effect 
of paclitaxel on inhibiting neointimal formation. In the era of DES, this new concept of drug-resistance could be applied to the treatment of instent 
restenosis and to the development of new DES.
